Steve Scala
Stock Analyst at TD Cowen
(2.82)
# 1,620
Out of 5,161 analysts
33
Total ratings
74.07%
Success rate
13.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Scala
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Hold | $100 → $120 | $115.56 | +3.84% | 2 | Jan 20, 2026 | |
| RPRX Royalty Pharma | Maintains: Buy | $42 → $45 | $45.62 | -1.36% | 2 | Dec 11, 2025 | |
| ABBV AbbVie | Maintains: Buy | $195 → $225 | $219.71 | +2.41% | 12 | Oct 7, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $59 | $58.94 | +0.11% | 3 | Oct 7, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $90 → $95 | $190.14 | -50.04% | 1 | Aug 12, 2024 | |
| PFE Pfizer | Downgrades: Market Perform | $32 | $26.59 | +20.37% | 1 | Jan 4, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $430 → $500 | $985.18 | -49.25% | 8 | May 23, 2023 | |
| NVS Novartis AG | Downgrades: Market Perform | $110 → $105 | $153.37 | -31.54% | 4 | Feb 1, 2021 |
Merck & Co.
Jan 20, 2026
Maintains: Hold
Price Target: $100 → $120
Current: $115.56
Upside: +3.84%
Royalty Pharma
Dec 11, 2025
Maintains: Buy
Price Target: $42 → $45
Current: $45.62
Upside: -1.36%
AbbVie
Oct 7, 2024
Maintains: Buy
Price Target: $195 → $225
Current: $219.71
Upside: +2.41%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Hold
Price Target: $53 → $59
Current: $58.94
Upside: +0.11%
AstraZeneca
Aug 12, 2024
Maintains: Buy
Price Target: $90 → $95
Current: $190.14
Upside: -50.04%
Pfizer
Jan 4, 2024
Downgrades: Market Perform
Price Target: $32
Current: $26.59
Upside: +20.37%
Eli Lilly and Company
May 23, 2023
Maintains: Outperform
Price Target: $430 → $500
Current: $985.18
Upside: -49.25%
Novartis AG
Feb 1, 2021
Downgrades: Market Perform
Price Target: $110 → $105
Current: $153.37
Upside: -31.54%